HK1216427A1 - 針對 的人抗體分子 - Google Patents

針對 的人抗體分子

Info

Publication number
HK1216427A1
HK1216427A1 HK16104446.4A HK16104446A HK1216427A1 HK 1216427 A1 HK1216427 A1 HK 1216427A1 HK 16104446 A HK16104446 A HK 16104446A HK 1216427 A1 HK1216427 A1 HK 1216427A1
Authority
HK
Hong Kong
Prior art keywords
human antibody
antibody molecules
molecules
human
antibody
Prior art date
Application number
HK16104446.4A
Other languages
English (en)
Inventor
David Monk Phillip
Jermutus Lutz
Raymond Minter Ralph
Patricia Shorrock Celia
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1216427A1 publication Critical patent/HK1216427A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16104446.4A 2003-07-15 2016-04-19 針對 的人抗體分子 HK1216427A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24

Publications (1)

Publication Number Publication Date
HK1216427A1 true HK1216427A1 (zh) 2016-11-11

Family

ID=44535047

Family Applications (3)

Application Number Title Priority Date Filing Date
HK07101860.8A HK1097853A1 (zh) 2003-07-15 2007-02-15 針對 的人抗體分子
HK11109456.5A HK1155185A1 (zh) 2003-07-15 2011-09-07 用於 的人抗體分子
HK16104446.4A HK1216427A1 (zh) 2003-07-15 2016-04-19 針對 的人抗體分子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK07101860.8A HK1097853A1 (zh) 2003-07-15 2007-02-15 針對 的人抗體分子
HK11109456.5A HK1155185A1 (zh) 2003-07-15 2011-09-07 用於 的人抗體分子

Country Status (8)

Country Link
JP (3) JP5519567B2 (zh)
KR (1) KR101073590B1 (zh)
AU (1) AU2011200308B2 (zh)
CY (1) CY1111467T1 (zh)
HK (3) HK1097853A1 (zh)
MX (1) MXPA06000258A (zh)
NO (2) NO338853B1 (zh)
RU (1) RU2009148270A (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016015785A (es) * 2014-06-18 2017-04-25 Medimmune Llc Metodos y medios de cultivo celular que comprenden n-acetilcisteina.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508179A (ja) * 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US20040023337A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
EP1461428B1 (en) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
HK1155185A1 (zh) 2012-05-11
MXPA06000258A (es) 2006-07-03
NO342727B1 (no) 2018-07-30
KR101073590B1 (ko) 2011-10-14
JP2014101372A (ja) 2014-06-05
JP2011147454A (ja) 2011-08-04
JP5922686B2 (ja) 2016-05-24
RU2009148270A (ru) 2011-06-27
KR20060054312A (ko) 2006-05-22
HK1097853A1 (zh) 2007-07-06
JP5519567B2 (ja) 2014-06-11
JP2016047843A (ja) 2016-04-07
CY1111467T1 (el) 2015-08-05
NO20060730L (no) 2006-04-10
AU2011200308A1 (en) 2011-02-17
AU2011200308B2 (en) 2011-07-28
NO338853B1 (no) 2016-10-24
NO20160707A1 (no) 2016-04-27

Similar Documents

Publication Publication Date Title
ME02245B (me) Anti-cd38 humana antitjela i njihove upotrebe
PL378412A1 (pl) Cząsteczki przeciwciał o specyficzności względem ludzkiej IL-1ß
ZA200604074B (en) Anti-IGFR1 antibody therapeutic combinations
PT1599504E (pt) Anticorpo modificado
IL173273A0 (en) Modified human igf-1r antibodies
HK1209759A1 (zh) 抗體及其用途
IL175710A0 (en) Anti-mpl antibody
IL175608A0 (en) Antibodies
SI2511297T1 (sl) Proti -CD38 humana protitelesa in njihova uporaba
EP1810979A4 (en) STABILIZED HUMAN IgG4 ANTIBODIES
EP1658095A4 (en) ANTI-CD3 ANTIBODY DESIMMUNISE
IL180789A0 (en) Human monoclonal antibodies against human il-4
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
ZA200606319B (en) Anti-CD38 human antibodies and uses therefor
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
EP1631315A4 (en) ANTIBODIES BINDING TO HUMAN CXCR3
IL172511A0 (en) Specific human antibodies
IL172510A0 (en) Antibodies and uses thereof
HK1216427A1 (zh) 針對 的人抗體分子
GB0306618D0 (en) Antibody
HK1209139A1 (zh) 經改良的抗體
GB0325391D0 (en) Human monoclonal antibodies
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa
GB0329711D0 (en) Antibodies
GB0317974D0 (en) Novel antibodies